|
🐜
|
Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.
43 auth.
E. Morris,
S. Jha,
C. Restaino,
P. Dayananth,
Hugh Y. Zhu,
A. Cooper,
D. Carr,
Yongi Deng,
Weihong Jin,
Stuart Black,
B. Long,
Jenny C. Liu,
Edward Dinunzio,
W. Windsor,
Rumin Zhang,
...
Shuxia Zhao,
M. Angagaw,
E. Pinheiro,
J. Desai,
L. Xiao,
G. Shipps,
A. Hruza,
James Wang,
J. Kelly,
S. Paliwal,
Xiaolei Gao,
B. S. Babu,
Liang Zhu,
Pierre Daublain,
Ling Zhang,
B. Lutterbach,
Marc Pelletier,
U. Philippar,
P. Siliphaivanh,
D. Witter,
P. Kirschmeier,
W. Bishop,
D. Hicklin,
D. Gilliland,
L. Jayaraman,
L. Zawel,
S. Fawell,
A. Samatar
|
9 |
2013 |
9
🐜
|
|
🐜
|
Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors.
12 auth.
T. Fischmann,
Catherine K. Smith,
Todd W. Mayhood,
J. Myers,
P. Reichert,
A. Mannarino,
...
D. Carr,
Hugh Y. Zhu,
J. Wong,
Rong-Sheng Yang,
H. Le,
V. Madison
|
7 |
2009 |
7
🐜
|
|
🐜
|
Discovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation Approach.
17 auth.
Chao Chen,
Hugh Y. Zhu,
F. Stauffer,
G. Caravatti,
S. Vollmer,
R. Machauer,
Philipp Holzer,
Henrik Möbitz,
C. Scheufler,
M. Klumpp,
...
R. Tiedt,
K. S. Beyer,
Keith Calkins,
Daniel A Guthy,
M. Kiffe,
Jeff Zhang,
C. Gaul
|
5 |
2016 |
5
🐜
|
|
🐜
|
Discovery of novel, dual mechanism ERK inhibitors by affinity selection screening of an inactive kinase.
17 auth.
Yongqi Deng,
G. Shipps,
A. Cooper,
J. English,
D. A. Annis,
D. Carr,
Y. Nan,
Tong Wang,
Hugh Y. Zhu,
C. Chuang,
...
P. Dayananth,
A. Hruza,
Li Xiao,
Weihong Jin,
P. Kirschmeier,
W. Windsor,
A. Samatar
|
5 |
2014 |
5
🐜
|
|
🐜
|
Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach.
15 auth.
Henrik Möbitz,
R. Machauer,
Philipp Holzer,
Andrea Vaupel,
F. Stauffer,
Christian Ragot,
G. Caravatti,
C. Scheufler,
C. Fernández,
U. Hommel,
...
R. Tiedt,
K. S. Beyer,
Chao Chen,
Hugh Y. Zhu,
C. Gaul
|
5 |
2017 |
5
🐜
|
|
🐜
|
MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology.
41 auth.
S. B. Boga,
Yongqi Deng,
Liang Zhu,
Y. Nan,
A. Cooper,
G. Shipps,
R. Doll,
N. Shih,
Hugh Y. Zhu,
Robert Sun,
Tong Wang,
S. Paliwal,
Hon-Chung Tsui,
Xiaolei Gao,
X. Yao,
...
J. Desai,
James Wang,
A. Alhassan,
J. Kelly,
Mehul D. Patel,
K. Muppalla,
S. Gudipati,
Li-kang Zhang,
A. Buevich,
D. Hesk,
D. Carr,
P. Dayananth,
Stuart Black,
H. Mei,
K. Cox,
B. Sherborne,
A. Hruza,
Li Xiao,
Weihong Jin,
B. Long,
Gongjie Liu,
S. Taylor,
P. Kirschmeier,
W. Windsor,
R. Bishop,
A. Samatar
|
5 |
2018 |
5
🐜
|
|
🐜
|
Discovery of Small-Molecule Antagonists of the H3K9me3 Binding to UHRF1 Tandem Tudor Domain
20 auth.
G. Senisterra,
Hugh Y. Zhu,
Xiao Luo,
Hailong Zhang,
Guoliang Xun,
Chunliang Lu,
W. Xiao,
T. Hajian,
P. Loppnau,
Irene Chau,
...
Fengling Li,
A. Allali-Hassani,
P. Atadja,
Counde Oyang,
E. Li,
P. Brown,
C. Arrowsmith,
Kehao Zhao,
Zhengtian Yu,
M. Vedadi
|
4 |
2018 |
4
🐜
|
|
🐜
|
Discovery of novel BTK inhibitors with carboxylic acids.
33 auth.
Xiaolei Gao,
James Wang,
Jian Liu,
D. Guiadeen,
Arto D Krikorian,
S. B. Boga,
A. Alhassan,
O. Selyutin,
Wensheng Yu,
Younong Yu,
Rajan Anand,
Shilan Liu,
Chundao Yang,
Hao Wu,
Jiaqiang Cai,
...
A. Cooper,
Hugh Y. Zhu,
K. Maloney,
Yinghong Gao,
T. Fischmann,
J. Presland,
M. Mansueto,
Zangwei Xu,
Erica Leccese,
J. Zhang-Hoover,
Ian Knemeyer,
C. Garlisi,
Nathan W Bays,
Peter Stivers,
P. Brandish,
A. Hicks,
R. Kim,
Joe Kozlowski
|
3 |
2017 |
3
🐜
|
|
🦁
|
Discovery of hydroxyaniline amides as selective Extracellular Regulated Kinase (Erk) inhibitors.
9 auth.
Hugh Y. Zhu,
J. Desai,
Yongqi Deng,
A. Cooper,
James Wang,
Jerry Shipps,
...
A. Samatar,
D. Carr,
W. Windsor
|
3 |
2015 |
3
🦁
|
